Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of PALI-2108 in Healthy Volunteers and Open-Label Study of a Patient Cohort With Ulcerative Colitis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Sep 2025 According to a Palisade Bio media release, Patient dosing in the Phase 1b FSCD study is expected to begin in 2H 2025.
17 Sep 2025 According to a Palisade Bio media release, results(Phase 1a Safety and Pharmacokinetics (n=84, SAD/MAD) and (hase 1b Ulcerative Colitis (UC) Cohort (n=5, 7 days)) from this trial are to be presented in an oral session at the STAR Consortium Annual Meeting
17 Sep 2025 Results published in the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com